Having in mind that KRAS G12C and BRAF mutations are expressed in a significant number of ILD/IPF cases with concurrent NSCLC, we must offer thorough genetic testing in these patients beyond EGFR and ALK testing. This evidence concerns the gene EGFR and interstitial lung disease.